Page 48 - Looking Statement News Today : Breaking News, Live

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

Published: August 31, 2023

LOS ANGELES, Aug. 31, 2023 -- Big Screen Entertainment Group is inviting individual and institutional investors, advisors and analysts to attend its real-time, interactive presentation at the next...

Source: marketscreener.com

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

Published: August 31, 2023

31.08.2023 - LOS ANGELES, Aug. 31, 2023 (GLOBE NEWSWIRE) - Big Screen Entertainment Group (OTC:BSEG) is inviting individual and institutional investors, advisors and analysts to attend its real-time, interactive presentation at the next Emerging Growth ...

Source: wallstreet-online.de

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | National Business

Published: August 29, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Aug 28, 2023--

Source: joplinglobe.com

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | Business

Published: August 29, 2023

PRINCETON, N.J.--(BUSINESS WIRE)--Aug 28, 2023--

Source: valdostadailytimes.com

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Published: August 29, 2023

Approval based on progression-free survival benefit demonstrated in Phase 3 KEYNOTE-811 trial KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient...

Source: marketscreener.com

Page 48 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Looking Statement Today - Breaking & Trending Today

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | National Business

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | Business

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

Page 48 - Looking Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Looking Statement Today - Breaking & Trending Today

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

Big Screen Entertainment Group to Present Company Update at The Emerging Growth Conference on September 7, 2023

U.S. FDA Approves Bristol Myers Squibb's Reblozyl&#xAE; (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | National Business

U.S. FDA Approves Bristol Myers Squibb's Reblozyl&#xAE; (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | Business

European Commission Approves KEYTRUDA&#xAE; (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS &#x2265;1)

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | National Business

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions | Business

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)